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Provider Information: Rotavirus VIS 
Many Vaccine Information Statements are available in Spanish and other languages. See 
www.immunize.org/vis. 
Two rotavirus vaccines are approved for use in the United States: 
• Rotarix® (RV1 - GlaxoSmithKline), a monovalent vaccine: 2-dose routine series at 2 and 4 
months 
• RotaTeq® (RV5 - Merck), a pentavalent vaccine: 3-dose routine series at 2, 4, and 6 months 
Additional ACIP recommendations for both vaccines: 
• Minimum age: 6 weeks 
• Maximum age for first dose: 14 weeks, 6 days  
(The series should not be initiated for infants 15 weeks, 0 days or older.) 
• Maximum age for final dose: 8 months, 0 days 
• Minimum intervals between doses: 4 weeks 
For children who start late or fall behind, recommendations can be found on CDC’s Pediatric Catch-Up 
Schedule: http://www.cdc.gov/vaccines/schedules/downloads/child/catchup-schedule-pr.pdf  
Contraindications and Precautions 
Contraindications: 
• A history of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of either rotavirus 
vaccine, or to any component of the vaccine being given. For a list of components for both 
Rotarix and RotaTeq, see the package inserts or  
http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf. 
Latex Allergy: 
o Rotarix: The tip cap and rubber plunger of the applicator contain latex. 
o RotaTeq: Does not contain latex. 
 
“Some experts prefer that infants with spina bifida or bladder exstrophy, who are at high risk 
for acquiring latex allergy, receive [RotaTeq] instead of [Rotarix] to minimize latex exposure 
in these children. However, if [Rotarix] is the only rotavirus vaccine available, it should be 
administered, because the benefit of vaccination is considered to be greater than the risk for 
sensitization.” 3 
 
• Severe combined immunodeficiency (“SCID”). 
(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5922a3.htm?s_cid=mm5922a3_e%0d%0a)  
• A history of intussusception. (Children with a history of intussusception are at greater risk of 




• Altered immunocompetence.  
For children with known or suspected altered immunocompetence, ACIP advises consultation 
with an immunologist or Infectious diseases specialist before administration of rotavirus vaccine. 
“Children and adults who are immunocompromised because of congenital immunodeficiency, 
hematopoietic transplantation, or solid organ transplantation sometimes experience severe or 
prolonged rotavirus gastroenteritis.” 3 
HIV Infection: Limited data from clinical trials do not indicate that rotavirus vaccines have a 
substantially different safety profile in HIV-infected infants who are clinically asymptomatic or 
mildly symptomatic, compared with infants who are not HIV infected. Two other considerations 
support vaccination of HIV-exposed or -infected infants in the United States. First, the HIV 
diagnosis might not be established in infants born to HIV-infected mothers by the time they reach 
the age of the first rotavirus vaccine dose. Only 3% or less of HIV-exposed infants in the United 
States will be determined to be HIV infected. Second, vaccine strains of rotavirus are 
considerably attenuated. 
• “The presence of a moderate or severe acute illness with or without a fever is a 
precaution to administration of all vaccines.... Vaccination should not be delayed because 
of the presence of mild respiratory tract illness or other mild acute illness with or without 
fever.” (ACIP General Recommendations on Immunization, p. 11)  




Intussusception is a disorder in which one segment of the intestine slides 
into another. The affected segments obstruct the bowel and block blood 
flow. 
Intussusception is the most common cause of acute bowel obstruction in 
infants. In the great majority of cases, the cause of the intussusception is 
not known.  
Before rotavirus vaccine introduction, each year in the United States:  
• About 1,900 infants developed intussusception – about 44 cases 
per 100,000 (1 in 2,300) infants by age 1 year.  
• About 37% of infants with intussusception required surgery. 
• About 4 infants (0.2% of those with intussusception) died.  
The baseline (background) rate of intussusception changes over the first year of life, with very low rates 
in the first month of life, rates increasing during the next 5 months to peak at age 6-7 months, and then 
decreasing.  
With early detection and treatment, nearly all infants with intussusception recover fully.  
 
Parents should be made aware of the signs of intussusception: 
Early signs and symptoms include sudden onset of episodes of severe colicky abdominal pain (which may 
initially last just a few minutes and recur several times an hour). Infants might draw their legs up to their 
chest during these episodes. Infants with intussusception may also vomit several times, have blood in the 
stool, appear lethargic or very irritable. 
Risk of Intussusception Following Vaccination 
Post-marketing studies indicate there is a small risk of intussusception from the currently licensed 
rotavirus vaccines. These studies on one or both of the vaccines were conducted in the United States, 
Australia, Mexico, and Brazil. 
Two main studies in the U.S. have evaluated post-licensure risk following use of rotavirus vaccines.  
• One study found an increased risk of intussusception during the first week following dose 1 and 
dose 2 of Rotarix. This study did not find a statistically significant increased risk of 
intussusception following RotaTeq.  
• Another study found an increased risk of intussusception following the dose 1 of RotaTeq, 
primarily during the first week. No increased risk was detected following doses 2 or 3.  
Studies in other countries have found increased risk of intussusception following both vaccines.  
Though there are inconsistent findings across some studies and lack of precision in the risk estimates, the 
data indicate that both currently licensed rotavirus vaccines are associated with a small risk of 
intussusception. Monitoring is continuing in the U.S. and these risk estimates may change when 
additional data become available. 
The rotavirus VIS describes the additional risk of intussusception from rotavirus vaccination overall, as 
an estimated range of 1 excess case in 20,000 to 100,000 vaccinated infants. Providers may use the above 
additional information as needed in discussions with parents.  
More information about the risk of intussusception following rotavirus vaccination, and about the safety 
of rotavirus vaccines in general, can be found at http://www.cdc.gov/vaccinesafety/vaccines/rotavsb.html. 
Benefits of vaccination  
Before the introduction of rotavirus vaccines in the U.S., rotavirus caused an estimated 20-60 deaths, 
55,000-70,000 hospitalizations, more than 200,000 emergency department visits and more than 400,000 
outpatient visits annually in children under 5. By age 5 years, almost all children had been infected by 
rotavirus and about 1 child in 70 was hospitalized for rotavirus disease. 
Based on post-marketing evaluations in the U.S., the currently licensed vaccines have been found to be 
highly (85%-90%) protective in U.S. children against rotavirus disease requiring hospitalization, and also 
highly (≥80%) protective in preventing emergency department care for rotavirus disease. Approximately 
40,000-50,000 hospitalizations for rotavirus disease have been prevented each year since 2008 in U.S. 
children aged <5 years.  
Risk/Benefit  
CDC continues to recommend that all U.S. infants (following the age and precaution/ 
contraindication criteria) receive rotavirus vaccine. The benefits of either vaccine outweigh the 
 
small excess risk of intussusception. Parents should be made aware of the small risk of 
intussusception, the signs and symptoms of intussusception, and the need for prompt care if these 
develop.  
Other Information 
• “ACIP supports vaccination of preterm infants according to the same schedule and precautions 
as full-term infants and under the following conditions: 
o the infant’s chronological age meets the age requirements for rotavirus vaccine (e.g., age 
6 weeks – 14 weeks and 6 days for dose 1), 
o the infant is clinically stable,  
o the vaccine is administered at the time of discharge from the NICU or nursery or after 
discharge from the NICU or nursery.” 3 
• Infants living in households with pregnant women should be vaccinated according to the same 
schedule as infants in households without pregnant women. 
 
The majority of women of childbearing age have preexisting immunity to rotavirus.  
• Infants living in households with immunocompromised persons can be vaccinated. 
 
The risk of an immunocompromised person contracting wild-type rotavirus disease from an 
unvaccinated infant is considered greater than the risk of vaccine virus-associated disease.  
• Post-marketing strain surveillance in the United States and other countries has occasionally 
detected RV5 vaccine-derived strains (reassortants, i.e., having genetic sequences from more than 
one RV5 strain) in stool samples of children with diarrhea. In some of these reports, the vaccine-
derived strain seemed to be the likely cause of the diarrheal illness. 
• A virus, or parts of a virus, called “porcine circovirus” have been detected in both rotavirus 
vaccines. There is no evidence that this virus is a safety risk or that it causes illness in humans. 
Questions & Answers about porcine circovirus in rotavirus vaccines from the World Health 
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